Literature DB >> 11387905

Remission of cold hemagglutinin disease induced by rituximab therapy.

T G Sparling, M Andricevic, H Wass.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11387905      PMCID： PMC81051     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  Remission of severe cold agglutinin disease after Rituximab therapy.

Authors:  N Layios; E Van Den Neste; E Jost; V Deneys; J M Scheiff; A Ferrant
Journal:  Leukemia       Date:  2001-01       Impact factor: 11.528

2.  Rituxan in the treatment of cold agglutinin disease.

Authors:  E J Lee; B Kueck
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

3.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Authors:  P McLaughlin; A J Grillo-López; B K Link; R Levy; M S Czuczman; M E Williams; M R Heyman; I Bence-Bruckler; C A White; F Cabanillas; V Jain; A D Ho; J Lister; K Wey; D Shen; B K Dallaire
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.